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tacrolimus and ciclosporin, and a randomised study which assessed tacrolimus’
relapse prevention ability. Azathioprine and psoralen-UVA were considered as res-
cue therapies after failure of tacrolimus or ciclosporin. Effectiveness was measured
in quality-adjusted life years (QALY) and life years in remission (LYr). Only direct
costs (drugs, medical visits, hospitalization, adverse event treatment and monitor-
ing) were incorporated. The main source for unit costs was the Portuguese National
Health System price list whilst utilities were based on a survey conducted with DA
patients. Time horizon was fixed at 1 year. Probabilistic sensitivity analysis was
conducted with Monte Carlo simulations. RESULTS: For each 100 patients treated
with tacrolimus instead of ciclosporin, mean gains of 0.99 QALY (95%CI: [0.98; 1.00])
and 2.76 LYr (95%CI: [2.72; 2.81]) were estimated. Additionally, tacrolimus utiliza-
tion leads to an overall cost reduction of 16,277€ (95%CI: [-17,619; -15,607]) thus
representing a dominant option. CONCLUSIONS: When compared against
ciclosporin, tacrolimus is a cost-saving and more effective therapeutic option for
the treatment of moderate to severe AD from the Portuguese societal perspective.
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OBJECTIVES:Atopic dermatitis (AD) is a chronic inflammatory itchy skin condition.
In a recent Spanish study the estimated prevalence of AD in children between 0 and
14 years old was 8.6%. Topical corticosteroids are currently the favoured treatment
for AD. However, their use is limited. Tacrolimus ointment has a demonstrated
efficacy in the treatment of moderate and severe AD in children. Twice-weekly
maintenance treatment has been approved and the aim of this study was to carry
out a cost-effective analysis comparing maintenance with standard reactive treat-
ment with tacrolimus ointment from the perspective of the Spanish NHS.
METHODS:An economic model was developed to compare maintenance and stan-
dard treatment patients for a period of 12 months. For those patients who discon-
tinued tacrolimus treatment before 1 year, resource use associated with post-dis-
continuation treatment was identified through a specially convened Advisory
Board with a group of clinical experts. Costs in 2012 euros were assigned to the
resources identified. Utility values were also inputted into the model. Results were
expressed in terms of total costs and cost/QALY. RESULTS: For patients with mod-
erate or severe AD, twice-weekly maintenance treatment with tacrolimus oint-
ment was shown to be more effective compared with the standard treatment reg-
imen. In the case of severe AD, maintenance treatment was also less costly
compared with standard treatment (939 vs. 1,084€). For moderate AD, the ICER was
1,981€/QALY which is considerably lower than the acceptable cost-effective
threshold (30,000€/QALY). CONCLUSIONS: Twice-weekly maintenance treatment
with tacrolimus ointment compared with standard reactive treatment would ap-
pear to be cost-effective and an additional option for clinicians for the treatment of
children suffering with moderate and severe AD in Spain.
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OBJECTIVES: To estimate the cost-effectiveness of linezolid for the treatment of
methicillin resistant staphylococcus aureus (MRSA) confirmed complicated skin
and soft tissue infections (cSSTI) under the Brazilian private health care system
perspective. METHODS: A cost-effectiveness analysis was developed based in a
decision tree model to simulate 28 days of treatment. A systematic revision of the
literature was developed over the efficacy and safety of the use of linezolid, van-
comicin, daptomicin and teicoplanin in patients diagnosed with MRSA-confirmed
cSSTI. Efficacy data used to input the economic model is informed in a published
meta-analysis. In this meta-analysis pooled efficacy estimates were generated
from clinical and microbiological determinations of success for the MRSA-sub-
groups in cSSTI clinical trials using a Bayesian meta-analytic approach (treatment
success rate: linezolide-84.4%, vancomicin-74.7%, daptomicina-78.1% and teico-
planina-74.7%). The treatment duration was 14 days for each first line treatment
and more 14 days for the second line treatment. Patients in treatment with lin-
ezolid stay 8 days in the hospital using venous linezolid and complete the treat-
ment with oral linezolid during 6 days, based on Itani et al. 2010. Patients in treat-
ment with vancomicin, daptomicin or teicoplanin stay 14 days in the hospital using
venous drugs. The costs and consequences of the disease treatment were com-
puted for each treatment alternative. Only direct medical costs were considered
based in official Brazilian costs databases. RESULTS: The incremental cost-effec-
tiveness analysis demonstrated that linezolide is the most economically attractive
drug, with better efficacy and lower cost than the comparators. The total cost per
patient with linezolide, vancomicin, daptomicin and teicoplanina were BRL26,365/
USD12,861, BRL36,421/USD17,766, BRL37,651/USD18,366, BRL37,984/USD18,529, re-
spectively. (US$ 1  R$ 2.05). CONCLUSIONS: Linezolid is the best therapeutic
option, with better efficacy and safety and lower cost, versus vancomicin, daptomi-
cin and teicoplanin for the treatment of patients diagnosed with MRSA-confirmed
cSSTI under Brazilian private perspective.
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OBJECTIVES: To evaluate the cost-effectiveness of ranibizumab versus best sup-
portive care and grid laser photocoagulation therapy in patients with macular
edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO).
METHODS: A Markov model was developed to compare treatment with ranibi-
zumab to best supportive care (CRVO) and grid laser photocoagulation therapy
(BRVO) in patients with ME secondary to RVO. Data from the BRAVO and CRUISE
clinical trials were used to estimate transition probabilities between health states,
defined by best corrected visual acuity (BCVA) and the frequency of adverse events.
Costs and utilities from published sources were associated with each treatment
and the model health states, and these were combined to predict the incremental
costs and outcomes for a cohort treated over a lifetime horizon. The model in-
cluded the costs associated with fellow eye involvement and the cost of blindness.
A health system perspective in the UK was used. RESULTS: In CRVO, ranibizumab
lead to a gain of 0.539 QALYs at an incremental cost of £9,216. The incremental
cost-effectiveness ratio (ICER) was £17,103 per QALY. In BRVO, ranibizumab was
shown to produce a gain of 0.518 QALYs at an incremental cost of £8,141. The ICER
was £15,710 per QALY. Both results were below the threshold range of £20,000 to
£30,000 which is regarded as representing acceptable cost-effectiveness in the UK.
Probabilistic sensitivity analysis suggests that the probability of cost-effectiveness
for ranibizumab at a £20,000 threshold is 60% in CRVO and 57% in BRVO.
CONCLUSIONS: Ranibizumab is a cost-effective therapy for treating patients with
ME secondary to both BRVO and CRVO compared to current standard of care in the
UK (laser in BRVO and observation in CRVO).
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OBJECTIVES: The value of ranibizumab as compared to standard care (laser pho-
tocoagulation in BRVO and observation in CRVO) was assessed within the frame-
work of a cost-utility analysis (CUA) from the Canadian health care and societal
perspectives. METHODS: Cost-utility of ranibizumab to the Canadian health care
system was analyzed using a Markov model that followed a cohort of 66 or 68 year
old patients (with BRVO or CRVO) over a lifetime time horizon. The model included
8 heath states as defined by best corrected visual acuity (BCVA) and 1 absorbing
state for death. Year 1 health state transitions were based on data from the BRAVO
and CRUISE trials, while year 2 transitions were based on data from the HORIZON
extension trial. From year 3 onwards, health state transitions were based on fixed
probabilities of maintaining or worsening BCVA. Health state utilities were derived
from both the literature and a Canadian utility study in RVO patients. Resource use
and costs were collected from clinical trials, published literature, and standard
Canadian sources. Costs and outcomes were discounted at 5% as recommended by
Canadian guidelines. RESULTS: From the health care perspective, patients receiv-
ing ranibizumab for BRVO accrued an additional 0.22 quality-adjusted life years
(QALYs) with a total estimated incremental cost of CAD$8,080, resulting in $36,725
per QALY gained. In CRVO, 0.41 QALYs and $11,466 were estimated, resulting in
$28,046 per QALY gained. From the societal perspective, considering costs related
to productivity losses, the analyses resulted in an incremental cost per QALY
gained of $11,266 for BRVO and $2,103 for CRVO. CONCLUSIONS: Compared to
standard care (laser photocoagulation in BRVO and observation in CRVO), ranibi-
zumab shows cost-effectiveness within commonly accepted cost per QALY thresh-
olds from both the health care and societal perspectives.
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OBJECTIVES:Quantify the cost effectiveness of treatments for macular edema (ME)
secondary to branch or central retinal vein occlusion (BRVO, CRVO) from U.S. pay-
er/societal perspectives. METHODS: A Markov model consisting of five visual acu-
ity (VA) health states and death was developed to quantify clinical outcomes, costs,
and quality-adjusted life-years (QALYs) associated with no treatment (observation)
or two-year treatment with ranibizumab monotherapy (six monthly injections; as
needed thereafter), laser photocoagulation (BRVO only), ranibizumab plus laser
(BRVO only), triamciniolone acetonide (CRVO only), or dexamethasone intravitreal
implant. Transition probabilities were based on patient-level data for ranibizumab
( laser) and published literature for the remaining alternatives. Health state-
specific costs and utilities were accrued for 13 years—approximate median survival
of an RVO patient—with costs and QALYs discounted 3% annually. Costs associ-
ated with treatment, adverse events, and impaired vision were expressed in 2011
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